CYTK
Price
$37.24
Change
-$1.65 (-4.24%)
Updated
Jul 18, 04:59 PM (EDT)
Capitalization
4.64B
13 days until earnings call
IOVA
Price
$2.23
Change
-$0.11 (-4.70%)
Updated
Jul 18, 04:59 PM (EDT)
Capitalization
781.41M
20 days until earnings call
Interact to see
Advertisement

CYTK vs IOVA

Header iconCYTK vs IOVA Comparison
Open Charts CYTK vs IOVABanner chart's image
Cytokinetics
Price$37.24
Change-$1.65 (-4.24%)
Volume$11.76K
Capitalization4.64B
Iovance Biotherapeutics
Price$2.23
Change-$0.11 (-4.70%)
Volume$61.85K
Capitalization781.41M
CYTK vs IOVA Comparison Chart in %
Loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IOVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTK vs. IOVA commentary
Jul 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a Hold and IOVA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 18, 2025
Stock price -- (CYTK: $38.89 vs. IOVA: $2.34)
Brand notoriety: CYTK and IOVA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 98% vs. IOVA: 195%
Market capitalization -- CYTK: $4.64B vs. IOVA: $781.41M
CYTK [@Biotechnology] is valued at $4.64B. IOVA’s [@Biotechnology] market capitalization is $781.41M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.62B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileIOVA’s FA Score has 1 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • IOVA’s FA Score: 1 green, 4 red.
According to our system of comparison, both CYTK and IOVA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 5 TA indicator(s) are bullish while IOVA’s TA Score has 5 bullish TA indicator(s).

  • CYTK’s TA Score: 5 bullish, 4 bearish.
  • IOVA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both CYTK and IOVA are a good buy in the short-term.

Price Growth

CYTK (@Biotechnology) experienced а +6.29% price change this week, while IOVA (@Biotechnology) price change was +21.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.49%. For the same industry, the average monthly price growth was +13.01%, and the average quarterly price growth was +34.43%.

Reported Earning Dates

CYTK is expected to report earnings on Oct 30, 2025.

IOVA is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+2.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($4.65B) has a higher market cap than IOVA($781M). CYTK YTD gains are higher at: -17.326 vs. IOVA (-68.378). IOVA has higher annual earnings (EBITDA): -354.01M vs. CYTK (-513.62M). CYTK has more cash in the bank: 938M vs. IOVA (360M). IOVA has less debt than CYTK: IOVA (53.7M) vs CYTK (791M). IOVA has higher revenues than CYTK: IOVA (213M) vs CYTK (19.2M).
CYTKIOVACYTK / IOVA
Capitalization4.65B781M595%
EBITDA-513.62M-354.01M145%
Gain YTD-17.326-68.37825%
P/E RatioN/AN/A-
Revenue19.2M213M9%
Total Cash938M360M261%
Total Debt791M53.7M1,473%
FUNDAMENTALS RATINGS
CYTK vs IOVA: Fundamental Ratings
CYTK
IOVA
OUTLOOK RATING
1..100
137
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
26
Undervalued
PROFIT vs RISK RATING
1..100
81100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
5965
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
5027

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IOVA's Valuation (26) in the Biotechnology industry is significantly better than the same rating for CYTK (100). This means that IOVA’s stock grew significantly faster than CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (81) in the Biotechnology industry is in the same range as IOVA (100). This means that CYTK’s stock grew similarly to IOVA’s over the last 12 months.

IOVA's SMR Rating (97) in the Biotechnology industry is in the same range as CYTK (100). This means that IOVA’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Price Growth Rating (59) in the Biotechnology industry is in the same range as IOVA (65). This means that CYTK’s stock grew similarly to IOVA’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for IOVA (100). This means that CYTK’s stock grew significantly faster than IOVA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKIOVA
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 19 days ago
78%
Bearish Trend 8 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
77%
Aroon
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IOVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCVFX32.29N/A
N/A
Fidelity Advisor Value C
IAXTX9.63N/A
N/A
VY® T. Rowe Price Divers Mid Cap Gr S2
JANVX84.06N/A
N/A
Janus Henderson Venture D
VEUPX183.27N/A
N/A
Vanguard European Stock Instl Plus
TNXAX10.49N/A
N/A
1290 Loomis Sayles Multi-Asset Income A